Lobaplatin Enhances Radioactive ¹²⁵I Seed-Induced Apoptosis and Anti-Proliferative Effect in Non-Small Cell Lung Cancer by Suppressing the AKT/mTOR Pathway

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2192
   PubMed Web of Science ®Google Scholar
• Reck M, Rabe KF, Longo DL. Precision diagnosis and treatment for advanced non-small-cell lung cancer. N Engl J Med. 2017;377(9):849–861. doi:10.1056/NEJMra1703413
   PubMed Web of Science ®Google Scholar
• Xie CY, Xu YP, Jin W, Lou LG. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer. Anticancer Drugs. 2012;23(7):698–705. doi:10.1097/CAD.0b013e328352cc10
   PubMed Web of Science ®Google Scholar
• Heelan RT, Hilaris BS, Anderson LL, et al. Lung tumors: percutaneous implantation of I-125 sources with CT treatment planning. Radiology. 1987;164(3):735–740. doi:10.1148/radiology.164.3.3615870
   PubMed Web of Science ®Google Scholar
• Jiang AG, Lu HY, Ding ZQ. Implantation of (125)I radioactive seeds via c-TBNA combined with chemotherapy in an advanced non-small-cell lung carcinoma patient. BMC Pulm Med. 2019;19(1):205. doi:10.1186/s12890-019-0974-8
   PubMed Web of Science ®Google Scholar
• Zhang W, Li J, Li R, Zhang Y, Han M, Ma W. Efficacy and safety of iodine-125 radioactive seeds brachytherapy for advanced non-small cell lung cancer-A meta-analysis. Brachytherapy. 2018;17(2):439–448. doi:10.1016/j.brachy.2017.11.015
   PubMed Web of Science ®Google Scholar
• Li J-R, Sun Y, Liu L. Radioactive seed implantation and lobaplatin chemotherapy are safe and effective in treating patients with advanced lung cancer. Asian Pac J Cancer Prev. 2015;16(9):4003–4006. doi:10.7314/apjcp.2015.16.9.4003
   PubMedGoogle Scholar
• Zhang J, Zhu Y, Dong M, Yang J, Weng W, Teng L. Iodine-125 interstitial brachytherapy reduces tumor growth via Warburg effect inhibition in non-small cell lung cancer A549 xenografts. Oncol Lett. 2018;16(5):5969–5977. doi:10.3892/ol.2018.9346
   PubMed Web of Science ®Google Scholar
• Zhang H, Chen R, Wang X, Zhang H, Zhu X, Chen J. Lobaplatin-induced apoptosis requires p53-mediated p38MAPK activation through ROS generation in non-small-cell lung cancer. Front Oncol. 2019;9:538. doi:10.3389/fonc.2019.00538
   PubMed Web of Science ®Google Scholar
• Ma D, Li S, Cui Y, et al. Paclitaxel increases the sensitivity of lung cancer cells to obaplatin via PI3K/Akt pathway. Oncol Lett. 2018;15(5):6211–6216. doi:10.3892/ol.2018.8086
   PubMed Web of Science ®Google Scholar
• Mossmann D, Park S, Hall MN. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat Rev Cancer. 2018;18(12):744–757. doi:10.1038/s41568-018-0074-8
   PubMed Web of Science ®Google Scholar
• Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004;10(6):594–601. doi:10.1038/nm1052
   PubMed Web of Science ®Google Scholar
• LoRusso PM. Inhibition of the PI3K/AKT/mTOR pathway in solid tumors. J Clin Oncol. 2016;34(31):3803–3815. doi:10.1200/JCO.2014.59.0018
   PubMed Web of Science ®Google Scholar
• Schettino C, Bareschino MA, Sacco PC, et al. New molecular targets in the treatment of NSCLC. Curr Pharm Des. 2013;19(30):5333–5343. doi:10.2174/13816128113199990343
   PubMed Web of Science ®Google Scholar
• Yang Y, Luo J, Zhai X, et al. Prognostic value of phospho-Akt in patients with non-small cell lung carcinoma: a meta-analysis. Int J Cancer. 2014;135(6):1417–1424. doi:10.1002/ijc.28788
   PubMed Web of Science ®Google Scholar
• Kim TJ, Lee JW, Song SY, et al. Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer. 2006;94(11):1678–1682. doi:10.1038/sj.bjc.6603180
   PubMed Web of Science ®Google Scholar
• Li X, Shang D, Shen H, Song J, Hao G, Tian Y. ZSCAN16 promotes proliferation, migration and invasion of bladder cancer via regulating NF-kB, AKT, mTOR, P38 and other genes. Biomed Pharmacother. 2020;126:110066. doi:10.1016/j.biopha.2020.110066
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhang Y, Xi S. Expression of Concern: upregulation of lncRNA HAGLROS enhances the development of nasopharyngeal carcinoma via modulating miR-100/ATG14 axis-mediated PI3K/AKT/mTOR signals. Artif Cells Nanomed Biotechnol. 2020;48(1):717. doi:10.1080/21691401.2020.1741909
   PubMed Web of Science ®Google Scholar
• Wang Y, Liu Y, Du X, Ma H, Yao J. Berberine reverses doxorubicin resistance by inhibiting autophagy through the PTEN/Akt/mTOR signaling pathway in breast cancer. Onco Targets Ther. 2020;13:1909–1919. doi:10.2147/OTT.S241632
   PubMed Web of Science ®Google Scholar
• Li D, Wang WJ, Wang YZ, Wang YB, Li YL. Lobaplatin promotes (125)I-induced apoptosis and inhibition of proliferation in hepatocellular carcinoma by upregulating PERK-eIF2alpha-ATF4-CHOP pathway. Cell Death Dis. 2019;10(10):744. doi:10.1038/s41419-019-1918-1
   PubMedGoogle Scholar
• Li D, Jia YM, Cao PK, Wang W, Liu B, Li YL. Combined effect of (125)I and gemcitabine on PANC-1 cells: cellular apoptosis and cell cycle arrest. J Cancer Res Ther. 2018;14(7):1476–1481. doi:10.4103/jcrt.JCRT_43_18
   PubMed Web of Science ®Google Scholar
• Larsen JE, Minna JD. Molecular biology of lung cancer: clinical implications. Clin Chest Med. 2011;32(4):703–740. doi:10.1016/j.ccm.2011.08.003
   PubMed Web of Science ®Google Scholar
• Yang F, Yu Y, Lei Q, et al. Lobaplatin arrests cell cycle progression, induces apoptosis and impairs migration and invasion in B16-F10 melanoma cell line in vitro. Biomed Pharmacother. 2015;69:402–408. doi:10.1016/j.biopha.2014.12.011
   PubMed Web of Science ®Google Scholar
• Teng X, Fan XF, Li Q, et al. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells. Oncol Rep. 2019;41(3):1875–1882. doi:10.3892/or.2019.6959
   PubMed Web of Science ®Google Scholar
• Liu F, Gao S, Yang Y, et al. Antitumor activity of curcumin by modulation of apoptosis and autophagy in human lung cancer A549 cells through inhibiting PI3K/Akt/mTOR pathway. Oncol Rep. 2018;39(3):1523–1531. doi:10.3892/or.2018.6188
   PubMed Web of Science ®Google Scholar
• Lee JH, Kim C, Um JY, Sethi G, Ahn KS. Casticin-induced inhibition of cell growth and survival are mediated through the dual modulation of Akt/mTOR signaling cascade. Cancers (Basel). 2019;11(2). doi:10.3390/cancers11020254
   Web of Science ®Google Scholar
• Harsha C, Banik K, Ang HL, et al. Targeting AKT/mTOR in oral cancer: mechanisms and advances in clinical trials. Int J Mol Sci. 2020;21(9). doi:10.3390/ijms21093285
   PubMed Web of Science ®Google Scholar
• Woo Y, Lee HJ, Jung YM, Jung YJ. mTOR-mediated antioxidant activation in solid tumor radioresistance. J Oncol. 2019;2019:5956867. doi:10.1155/2019/5956867
   PubMed Web of Science ®Google Scholar